简介:目的探讨直肠癌远端黏膜Cox-2及Bcl-2蛋白的表达情况,判断直肠癌手术的远端安全切除范围。方法应用免疫组织化学S—P法检测54例直肠癌远端2cm及3cm黏膜组织、肿瘤组织和20例手术切除的直肠正常黏膜组织中Cox-2和Bcl-2蛋白的表达情况。结果直肠癌远端2cm、3cm黏膜组织与肿瘤组织中Cox-2和Bcl-2蛋白的表达差异有统计学意义(P〈0.05),与直肠正常黏膜组织中的表达差异则无统计学意义(P〉0.05)。在不同的肿瘤临床病理参数中,直肠癌远端2cm、3cm黏膜组织中Cox-2和Bcl-2蛋白的表达也无明显差异(均P〉0.05)结论直肠癌远端2cm、3cm黏膜组织中Cox-2与Bcl-2蛋白的表达与正常组织无差异,提示直肠癌远端切除2cm已经足够。
简介:目的:体外观察黄芪对人喉癌细胞系Hep-2的抑制增殖和转移能力的作用并探讨其作用机制。方法:用20、100、200μg/ml的黄芪作用于Hep-2细胞24h,MTT法检测细胞增殖,流式细胞仪检测细胞周期分布和细胞凋亡率,侵袭实验观察药物对Hep-2细胞侵袭转移能力影响,AO/EB染色观察细胞凋亡,Westernblot检测Bcl-2和Bax蛋白的表达。结果:MTT结果显示黄芪对Hep-2细胞的增殖抑制作用具有明显的剂量依赖性;流式细胞仪检测发现随着黄芪浓度增高,细胞凋亡率逐渐升高,统计学分析,各实验组之间及其与对照组之间的差异均有统计学意义(P〈0.05);AO/EB染色后可见典型细胞凋亡的形态变化;Hep-2细胞体外侵袭能力明显受抑制,存在剂量依赖性;Westernblot检测显示黄芪可剂量依赖性地抑制Bcl-2蛋白表达。结论:黄芪可通过抑制Bcl-2蛋白表达,上调Bax表达,引起喉癌细胞增殖抑制和凋亡,发挥抗癌作用。
简介:Objective:Toinvestigatetheimpactofbeta-elemeneinjectiononthegrowthandalpha-tubuleofhumanhepatocarcinomaHepG2cells.Methods:CellproliferationwasassessedbyMTTassay.Cellcycledistributionwasdetectedbyflowcytometry(FCM).ThemRNAexpressionofalpha-tubulinwasmeasuredbyRT-PCR.Westernblotanalysiswasusedtodetermineproteinexpressionofalpha-tubulinandthepolymerizationoftubulin.Results:Beta-elemeneinjectioninhibitedHepG2cellsproliferationinadose-andtime-dependentmanner;FCManalysisindicatedbeta-elemeneinjectioninducedcellcyclearrestedatSphase.RT-PCRandwesternblotanalysisshowedthatbeta-elemeneinjectiondown-regulatedalpha-tublinatbothmRNAandproteinlevels,presentingadose-dependentmanner.Moreover,beta-elemeneinjectionreducedthepolymerizationofmicrotubulesinadose-dependentmanner.Conclusions:Beta-elemeneinjectioncaninhibittheproliferationofhepatomaHepG2cellsandinducecellapoptosis,themechanismmightbepartlyrelatedtothedown-regulationofalpha-tubulinandinhibitionofmicrotubularpolymerization.
简介:Chronicalcoholconsumptionisamajorriskfactorworldwideaffectingsignificantlybothmortalityandyearsoflifelost(YLL)(1).Ca.5%ofthewesternworldshowriskyalcoholconsumptionandinsomecountriessuchasChinaaregionalyearlyincreaseofalcoholconsumptionofover400%hasbeenobservedrecently(2,3).Theliveris
简介:PURPOSE:Todeterminethesafetyandefficacyofgefitinib,anepidermalgrowthfactorreceptor(EGFR)tyrosinekinaseinhibitor,incombinationwithradiationfornewlydiagnosedglioblastoma(GBM)patients.METHODSANDMATERIALS:BetweenMarch21,2002,andMay3,2004,RadiationTherapyOncologyGroup(RTOG)0211enrolled31and147GBMpatientsinthephase1and2arms,respectively.Treatmentconsistedofdailyoralgefinitnibstartedatthetimeofconventionalcranialradiationtherapy(RT)andcontinuedpostRTfor18monthsoruntilprogression.Tissuemicroarraysfrom68caseswereanalyzedforEGFRexpression.RESULTS:Themaximumtolerateddose(MTD)ofgefitinibwasdeterminedtobe500mginpatientsonnon-enzyme-inducinganticonvulsantdrugs(non-EIAEDs).Allpatientsinthephase2componentweretreatedatagefitinibdoseof500mg;patientsreceivingEIADSscouldbeescalatedto750mg.Themostcommonsideeffectsofgefitinibincombinationwithradiationweredermatologicandgastrointestinal.Mediansurvivalwas11.5monthsforpatientstreatedperprotocol.Therewasnooverallsurvivalbenefitforpatientstreatedwithgefitinib+RTwhencomparedwithahistoricalcohortofpatientstreatedwithRTalone,matchedbyRTOGrecursivepartitioninganalysis(RPA)classdistribution.Youngeragewassignificantlyassociatedwithbetteroutcome.Perprotocolstratification,EGFRexpressionwasnotfoundtobeofprognosticvalueforgefitinib+RT-treatedpatients.CONCLUSIONS:TheadditionofgefitinibtoRTiswelltolerated.MediansurvivalofRTOG0211patientstreatedwithRTwithconcurrentandadjuvantgefitinibwassimilartothatinahistoricalcontrolcohorttreatedwithradiationalone.
简介:目的检测Survivin和Skp2蛋白在非小细胞肺癌中的表达,探讨其相互关系及临床意义。方法用实时定量PCR的方法检测30例非小细胞肺癌组织及其对应的癌旁组织中survivinmRNA的表达,应用免疫组织化学法检测50例非小细胞肺癌组织中Survivin和Skp2的表达,统计Survivin与病理特征及Skp2的关系。结果76.7%(23/30)肿瘤组织survivinmRNA表达量明显高于对应的癌旁组织。Survivin蛋白在癌组织的阳性表达率(74.0%)显著高于癌旁组织(16.7%),χ2=25.9,P〈0.001。Skp2在非小细胞肺癌组织中的阳性表达率(70.0%)也显著高于癌旁组织(20.0%),χ2=18.8,P〈0.001)。Survivin表达与非小细胞肺癌的病理类型、分化程度、肿瘤分期以及是否有淋巴结转移无统计学意义的相关性(P〉0.05)。Survivin表达与Skp2表达呈正相关(χ2=8.32,P〈0.05)。结论Survivin在肺癌组织中高表达,其阳性表达率与肿瘤病理类型、肿瘤分期、细胞分化程度和淋巴结转移无明显相关性,与Skp2表达呈正相关。
简介:转化生长因子-β(transforminggrowthfactor-β,TGF-β)作为一种多功能生长因子,具有抑制神经干细胞增殖以及诱导其分化的功能。然而,TGF-β在肿瘤形成过程中具有双重性,在肿瘤形成初期TGF-β可作为抑癌因子抑制细胞增殖.促进细胞分化或凋亡:而在肿瘤发展期,TGF-β却通过促进肿瘤增殖、刺激血管增生和抑制免疫反应而成为促癌因子。目前TGF-β由抑癌因子转变成促癌因子的分子机制尚不清楚。研究发现,TGF-β信号通路在高级别胶质瘤中高度激活表达,并且TGF-β活性高的胶质瘤患者的临床预后极差。胶质瘤干/祖细胞作为胶质瘤发生发展的起源.是胶质瘤治疗成败的关键。因此,研究TGF-β信号通路在胶质瘤干/祖细胞中的生物学效应显得至关重要。本文就TGF-β信号通路在肿瘤干细胞和胶质瘤干/祖细胞的增殖、分化、血管生成、转移等方面的作用作一综述.
简介:Objective:B-celllymphoma2(Bcl-2)isanimportantmemberoftheBcl-2familyofproteinsthatregulatetheinductionofapoptosis.ThisstudyaimstoinvestigatewhetherBcl-2smallinterferingRNA(siRNA)combinedwithmiR-15aoligonucleotides(ODN)couldenhancemethotrexate(MTX)-inducedapoptosisinRajicells.Methods:ChemicallysynthesizedmiR-15aODNandBcl-2siRNAweretransfectedinRajicellsbyusingaHiPerFectTransfectionReagentandthencombinedwithMTX.ExpressionlevelsofBcl-2proteinweredetectedbyWesternblot.CellproliferationwasdeterminedbyCCK8assay.TherateofcellapoptosiswasdeterminedbyAnnexinV/PIdoublestaining.ThemorphologyofapoptoticcellswasobservedbyHoechst-33258staining.Results:AfterthecellsweretransfectedwithmiR-15aODNcombinedwithBcl-2siRNA,Bcl-2proteinlevelswereevidentlydecreased.CCK8assayshowedthatcellproliferationwassignificantlydecreasedandwassignificantlylowerinmiR-15aODNcombinedwithBcl-2siRNAplusMTXgroupthaninmiR-15aODNwithmethotrexategroup,Bcl-2siRNAwithMTXgroup,andsingleMTXgroup(P<0.05).Hoechst33258stainingrevealednumerousapoptoticcells.AnnexinV/PIdoublestainingshowedthattheapoptoticrateswere(13.13±1.60)%,(34.47±2.96)%,(32.87±3.48)%,and(45.47±2.16)%inMTX,Bcl-2siRNAplusMTX,miR-15aODNplusMTX,andmiR-15aODNcombinedwithBcl-2siRNAplusMTXgroups,respectively.Amongthesegroups,theapoptoticrateofmiR-15aODNcombinedwithBcl-2siRNAplusMTXgroupwasthehighest;thisapoptoticratewasalsosignificantlydifferentfromthatofmiR-15aODNorBcl-2siRNAplusMTX(P<0.05).Conclusions:Bcl-2siRNAcombinedwithmiR-15aODNcouldenhanceMTX-inducedapoptosisinRajicells.Bcl-2siRNAandmiR-15acombinedwithMTXmaybeausefulapproachtoimprovethetreatmenteffectsonlymphoma.更多还原
简介:目的探讨糖酵解抑制剂2-脱氧-D-葡萄糖(2-deoxy-D-glucose,2-DG)与5-氟尿嘧啶(5-Fu)单独及联合应用对人胃癌细胞MGC-803增殖及凋亡的影响.方法将2-DG(10mmol/L)、及5-Fu(5.0μg/L)单药及联合用药作用于人胃癌细胞MGC-803,MTT法检测各组细胞的生长抑制率,流式细胞仪检测各组细胞凋亡情况.结果联合用药组(2-DG+5-Fu)对MGC-803增殖抑制率为(70.93±3.84)%,显著高于2-DG组(30.61±1.72)%和5-Fu组(47.08±4.34)%,差异有统计学意义(P<0.05).联合用药组肿瘤细胞凋亡率为(38.96±2.62)%,2-DG、5-Fu单药组肿瘤细胞凋亡率分别为(15.70±1.42)%、(25.56±2.64)%,联合用药组分别与单药组比较,差异有统计学意义(P<0.05).结论2-DG能有效抑制人胃癌细胞MGC-803细胞生长增殖,并诱导其凋亡;2-DG与5-Fu联合应用抗肿瘤作用明显增强.
简介:Objective:Thisstudyaimstoinvestigatetheclinicopathologicsignificanceoflymphaticvesselinvasion(LVI)labeledbyD2-40monoclonalantibodyinesophagealsquamouscellcarcinoma(ESCC).Methods:ImmunohistochemicalassaywasusedtodetecttheexpressionofD2-40andLVIin107ESCCpatients.Then,thecorrelationbetweentheclinicopathologicfeatureandtheoverallsurvivaltimeofthepatientswasanalyzed.Results:Thelymphnodemetastasisrateswere70%and21%intheLVI-positiveandLVI-negativegroups,respectively.ThenodalmetastasisratewashigherintheLVI-positivegroupthanintheLVI-negativegroup.MultivariateregressionanalysisshowedthatLVIwasrelatedtonodalmetastasis(P<0.001).Themediansurvivaltimeofthepatientswas26and43monthsintheLVI-positiveandLVI-negativegroups,respectively.Althoughunivariateregressionanalysisshowedsignificantdifferencebetweenthetwogroups(P=0.014),multivariateregressionanalysisrevealedthatLVIwasnotanindependentprognosticfactorforoverallsurvivalintheESCCpatients(P=0.062).Lymphaticnodemetastasis(P=0.031),clinicalstage(P=0.019),andresidualtumor(P=0.026)weretheindependentprognosticfactors.Conclusion:LVIlabeledbyD2-40monoclonalantibodyisariskfactorpredictiveoflymphnodemetastasisinESCCpatients.
简介:Objective:TheaimofthepresentstudywastoinvestigateantioxidantandtheanticancerigenactivityofamethanolextractfromArtemisiaprincepsvar.orientalis(APME),awell-knowntraditionalherbalmedicineinAsia,inhepatocellularcancercells.Methods:ToevaluatetheantioxidantactivityofAPME,reactiveoxygenspecies(ROS)andtheantioxidantenzymes,superoxidedismutase(SOD)andcatalasewereinvestigatedinHepG2cellsexposedtoAPME(5,100,and200μg/mL)for72h.Then,toevaluatetheanticanceractivityofAPME,weinvestigatedtheproliferationandapoptosisinductionofHepG2andHep3BcellsexposedtoAPME(1-200μg/mL)for24,48,and72h.Results:APMEdose-dependentlyreducedthegenerationofROSinthepresenceofH2O2comparedwithcontrolcells.Furthermore,itincreasedcatalaseandSODactivity.Moreover,APMEinhibitedcellproliferationinadose-andtime-dependentmanner,butatconcentrationslowerthan100μg/mL,theinhibitionwaslessdose-dependentthantime-dependent.HepG2andHep3Bcellsexposedto5,100,and200μg/mLAPMEfor72hunderwentcellcyclearrestandapoptosis.ExposuretoAPMEresultedinasignificantincreaseinthenumberofcellsinG1phaseandadecreaseintheG2/Mphasecellpopulation.Inaddition,APMEinducedP53expressionofHepG2cellsinadose-dependentmanner,andplayedaroleinthedownregulationofBcl-2andupregulationofBaxinbothHepG2andHep3Bcells.Conclusions:TheseresultsindicatethepotentialroleofAPMEasanantioxidantandanticancerigenagentinhepatocarcinomacelllines.
简介:Objective:Squamousesophagealcarcinomaishighlyprevalentindevelopingcountries,especiallyinChina.TuBeiMu(TBM),atraditionalfolkmedicine,hasbeenusedtotreatesophagealsquamouscellcarcinoma(ESCC)foralongterm.tubeimosideI(TBMS1)isthemaincomponentofTBM,exhibitinggreatanticancerpotential.Inthisstudy,weinvestigatedthemechanismofTBMS1cytotoxiceffectonEC109cells.Methods:Comparativenuclearproteomicapproachwasappliedinthecurrentstudyandweidentifiedseveralalteredproteinspots.Furtherbiochemicalstudieswerecarriedouttodetectthemitochondrialmembranepotential,cellcycleandcorrespondingproteins’expressionandlocation.Results:SubcellularproteomicstudyinthenucleusfromEC109cellsrevealedthatalteredproteinswereassociatedwithmitochondrialfunctionandcellproliferation.FurtherbiochemicalstudiesshowedthatTBMS1-inducedmoleculareventswererelatedtomitochondria-inducedintrinsicapoptosisandP21-cyclinB1/cdc2complex-relatedG2/Mcellcyclearrest.Conclusions:ConsideringtheconventionalapplicationofTBMinesophagealcancer,TBMS1thereforemayhaveagreatpotentialasachemotherapeuticdrugcandidateforESCC.
简介:目的靶向高迁移率族蛋白1(highmobilitygroupprotein,HMGBl)的小干扰RNA(siRNA)转染胃癌HGC-27细胞株抑制HMGBl基因表达,探讨其对胃癌细胞增殖、侵袭和迁移的影响。方法将靶向HMGB1的siRNA在脂质体介导下转染胃癌HGC-27细胞,Westernblot检测转染后细胞HMGB1蛋白表达变化,通过MTT实验检测转染后细胞的增殖活性,细胞划痕实验检测细胞侵袭和迁移能力。结果空白转染组、control-siRNA组和HMGB1干扰组HMGB1蛋白相对表达水平分别为(0.940±0.059)、(0.927±0.051)和(0.393±0.033),HMGB1干扰组蛋白表达水平明显下降,差异有统计学意义(P<0.05)。MTT和细胞划痕实验显示,与对照组相比,HMGB1干扰组细胞增殖缓慢,细胞迁移率明显降低,差异有统计学意义(P<0.05)。结论应用靶向siRNA沉默胃癌HGC-27细胞HMGB1基因表达可抑制其增殖、侵袭和迁移能力,具有抗肿瘤作用,HMGBl有望成为胃癌治疗的一个潜在靶点。
简介:目的探讨5-氮杂-2’-脱氧胞苷(5-Aza—CdR,DAC)与顺铂(cisplatin,PDD)联合应用对人三阴性乳腺癌细胞株MDA—MB-231体外增殖及凋亡的影响。方法实验分组:5txMDAC处理组(DAC组),15txMPDD处理组(PDD组),2.5txMDAC与8txMPDD同步处理组(DAC+PDD组),2.5μMDAC与8μMPDD序贯处理组(DAC→PDD组)及空白对照组。分别以MTT法和流式细胞术(FCM)测定各处理组MDA—MB-231细胞的增殖、凋亡情况,以q值评价两药的联合效应。结果DAC组的24h、48h、72h增殖抑制率分别为(8.12±0.79)%、(21.72±1.60)%及(30.39±1.31)%;PDD组为(35.14±2.OO)%、(49.22±1.01)%及(65.52±1.53)%;DAC+PDD组为(54.25±3.82)%、(68.89±1.52)%及(87.26±2.37)%;DAC→PDD组为(6.84±0.68)%、(67.64±0.91)%及(88.764-3.54)%。联合组较单药组增殖抑制率均显著升高(P〈0.01)。DAC+PDD组、DAC→PDD组24h、48h、72h的q值分别为1.12、1.14、1.15和0、1.12、1.17,两药联合有增效作用。对照组、DAC组、PDD组、DAC+PDD组、DAc—PDD组24h、48h、72h凋亡率分别为(1.57±0.38)%、(1.83±0.27)%、(2.26±0.42)%:(10.41±0.70)%、(15.37±0.74)%、(21.39±1.22)%;(16.63±0.65)%、(21.89±1.20)%、(30.39±2.20)%;(21.42±1.11)%、(33.86±1.16)%、(42.92±1.16)%;(8.26±0.68)%、(28.98±1.01)%、(41.98±1.12)%。联合组较单药组及对照组凋亡率显著升高(P〈0.01)。结论DAC与PDD均能抑制MDA—MB-231细胞株的增殖,促进其凋亡,且两者联合有增效作用。
简介:目的:探讨毒物代谢酶NAT1、NAT2基因多态性与广东地区汉族人群喉癌遗传易感性的关系。方法:采用病例-对照研究的方法,检测233例广东地区汉族喉癌和102例健康对照组外周血中NAT1(NAT1*4,NAT1*11,NAT1*10,NAT1*3)、NAT2(WT、M1、M2和M3)基因多态性。结合病历资料分析NAT1、NAT2多态基因与喉癌临床病理特征之间的关系。结果:喉癌患者携带NAT2快基因表型(18.88%)频率小于正常对照组(45.1%)(OR=2.53,P=0.00)。NAT2慢基因表型与重度吸烟在喉癌致病过程中有协同作用(P=0.013,OR=3.42)。NAT2基因表型与喉癌的临床病理特征无关。喉癌与对照组中NAT1多态基因频率无显著性差别。结论:NAT2快基因表型与喉癌的易感性关联,易感性与吸烟发生协同作用。NAT2基因多态性不影响喉癌的发展过程及预后。NAT1基因多态性可能与喉癌的遗传易感性无关。